Pith. sign in

REVIEW

From conception to clinical trial: IViST -- the first multi-sensor-based platform for real-time In Vivo dosimetry and Source Tracking in HDR brachytherapy

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2006.08031 v1 pith:WOGDP3KY submitted 2020-06-14 physics.med-ph

From conception to clinical trial: IViST -- the first multi-sensor-based platform for real-time In Vivo dosimetry and Source Tracking in HDR brachytherapy

classification physics.med-ph
keywords ivistplatformsourcereal-timebrachytherapyclinicaldosimetrydwell
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

This study aims to introduce IViST (In Vivo Source Tracking), a novel multi-sensors dosimetry platform for real-time treatment monitoring in HDR brachytherapy. IViST is a platform that comprises 3 parts: 1) an optimized and characterized multi-point plastic scintillator dosimeter (3 points mPSD; using BCF-60, BCF-12, and BCF-10 scintillators), 2) a compact assembly of photomultiplier tubes (PMTs) coupled to dichroic mirrors and filters for high-sensitivity scintillation light collection, and 3) a Python-based graphical user interface used for system management and signal processing. IViST can simultaneously measure dose, triangulate source position, and measure dwell time. By making 100 000 measurements/s, IViST samples enough data to quickly perform key QA/QC tasks such as identifying wrong individual dwell time or interchanged transfer tubes. By using 3 co-linear sensors and planned information for an implant geometry (from DICOM RT), the platform can also triangulate source position in real-time. A clinical trial is presently on-going using the IViST system.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.